Immucell (ICCC) Enterprise Value (2010 - 2026)
Immucell's (ICCC) quarterly Enterprise Value came in at -$3.8 million in Q4 2025, down 1.29% YoY from -$3.9 million in Q4 2024, and up 2.04% on a QoQ basis from -$3.9 million in Q3 2025.
Immucell (ICCC) Enterprise Value (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Enterprise Value data on file, last reported at -$3.8 million in Q4 2025.
- Quarterly Enterprise Value fell 1.29% year-over-year to -$3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.8 million (down 1.29% YoY) and the FY2025 annual result came in at -$3.8 million, down 1.29% from the prior year.
- Enterprise Value grew to -$3.8 million in Q4 2025, from -$3.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$960347.0 in Q1 2024 to a low of -$11.8 million in Q1 2022.
- A 5-year average of -$5.6 million and a median of -$4.2 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value jumped 86.83% — and 2025, when it tumbled 378.93%.
- Tracing ICCC's Enterprise Value over 5 years: stood at -$10.2 million in 2021, then jumped by 43.14% to -$5.8 million in 2022, then soared by 83.1% to -$978741.0 in 2023, then sank by 283.99% to -$3.8 million in 2024, then dropped by 1.29% to -$3.8 million in 2025.
- The last three Enterprise Value figures came in at -$3.8 million (Q4 2025), -$3.9 million (Q3 2025), and -$6.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 2.12 Bn |
| 10 | Immucell | 91.37 Mn | 82.51 Mn | 2.44 Mn | -8.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.86 Mn |
| Dec 31, 2025 | -3.81 Mn |
| Sep 30, 2025 | -3.89 Mn |
| Jun 30, 2025 | -6.00 Mn |
| Mar 31, 2025 | -4.60 Mn |
| Dec 31, 2024 | -3.76 Mn |
| Sep 30, 2024 | -3.81 Mn |
| Jun 30, 2024 | -1.32 Mn |
| Mar 31, 2024 | -960,347.00 |
| Dec 31, 2023 | -978,741.00 |
| Sep 30, 2023 | -1.99 Mn |
| Jun 30, 2023 | -1.45 Mn |
| Mar 31, 2023 | -3.10 Mn |
| Dec 31, 2022 | -5.79 Mn |
| Sep 30, 2022 | -8.83 Mn |
| Jun 30, 2022 | -11.04 Mn |
| Mar 31, 2022 | -11.82 Mn |
| Dec 31, 2021 | -10.19 Mn |
| Sep 30, 2021 | -10.50 Mn |
| Jun 30, 2021 | -10.70 Mn |